Cargando…
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML). However, the long-term survival of AML with unfavorable factors remains unsatisfactory. The latest data indicate that...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880983/ https://www.ncbi.nlm.nih.gov/pubmed/20416083 http://dx.doi.org/10.1186/1756-8722-3-17 |